Evidence map›Paper›PMID 33776987›Full record

ArticleFrontiers in immunology2020

Reduction of Allergic Lung Disease by Mucosal Application of

Elke Korb, Mirjana Drinić, Angelika Wagner, Nora Geissler, Aleksandra Inic-Kanada, Roman Peschke, Anja Joachim, Ursula Wiedermann, Irma Schabussova

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Frontiers in immunology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Elke KorbInstitute of Specific Prophylaxis and Tropical Medicine, Medical University of Vienna, Vienna, Austria.
Mirjana DrinićInstitute of Specific Prophylaxis and Tropical Medicine, Medical University of Vienna, Vienna, Austria.
Angelika WagnerInstitute of Specific Prophylaxis and Tropical Medicine, Medical University of Vienna, Vienna, Austria.
Nora GeisslerInstitute of Specific Prophylaxis and Tropical Medicine, Medical University of Vienna, Vienna, Austria.
Aleksandra Inic-KanadaInstitute of Specific Prophylaxis and Tropical Medicine, Medical University of Vienna, Vienna, Austria.
Roman PeschkeDepartment of Pathobiology, Institute of Parasitology, University of Veterinary Medicine Vienna, Vienna, Austria.
Anja JoachimDepartment of Pathobiology, Institute of Parasitology, University of Veterinary Medicine Vienna, Vienna, Austria.
Ursula WiedermannInstitute of Specific Prophylaxis and Tropical Medicine, Medical University of Vienna, Vienna, Austria.
Irma SchabussovaInstitute of Specific Prophylaxis and Tropical Medicine, Medical University of Vienna, Vienna, Austria.
Medical University of Vienna · ATUniversity of Veterinary Medicine Vienna · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The hygiene hypothesis suggests a link between parasitic infections and immune disorders, such as allergic diseases. We previously showed that infection with Methods: Mice were intranasally treated with TLA either i) prior to sensitization, ii) during sensitization and challenge, or iii) after sensitization with ovalbumin (OVA). Recruitment of inflammatory cells to the lung, cytokine levels in restimulated lung and spleen cell cultures as well as levels of OVA-specific antibodies in serum were measured. In parallel, the effect of native TLA, heat-inactivated (hiTLA) or deglycosylated TLA (dgTLA) on sensitized splenocytes was evaluated Results: When applied together with OVA i) during systemic sensitization and local challenge or ii) exclusively during local challenge, TLA reduced infiltration of eosinophils into the lung, OVA-specific type 2 cytokines in restimulated lung cell cultures, and partially, type 2 cytokines in restimulated spleen cell cultures in comparison to allergic controls. No beneficial effect was observed when TLA was applied prior to the start of sensitization. Analysis of epitope sugars on TLA indicated a high abundance of mannose, fucose, N-acetylglucosamine, and N-acetylgalactosamine. Deglycosylation of TLA, but not heat-inactivation, abolished the potential of TLA to reduce type 2 responses Conclusion: We showed that mucosal application of TLA reduced the development of experimental allergy in mice. The beneficial effects depended on the timing of the application in relation to the time point of sensitization. Not only co-application, but also therapy in sensitized/allergic animals with native TLA reduced local allergic responses. Furthermore, we show that TLA is highly glycosylated and glycoconjugates seem to play a role in anti-allergic effects. In summary, given the powerful modulatory effect that TLA exhibits, understanding its exact mechanisms of action may lead to the development of novel immunomodulators in clinical application.

Indexed as

AllergensAnimalsAntigens, ProtozoanCarbohydratesCell LineChlorocebus aethiopsCytokinesFemaleHypersensitivityImmunologic FactorsLungLung DiseasesMiceMice, Inbred BALB COvalbuminRespiratory MucosaAllergensAntigens, ProtozoanCarbohydratesCytokinesImmunologic FactorsOvalbuminallergic airway inflammationcarbohydratesdeglycosylationhygiene hypothesisimmunomodulationparasitestachyzoites lysate antigenToxoplasma gondii

Identifiers

PMID33776987
PMCPMC7988086
OpenAlexW3134684454

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.